Bodybuilding supplements co. announces joint venture with GNC
DOVER, Del. Extreme Physical Performance on Wednesday announced a new joint venture with General Nutrition Centers in distribution of its bodybuilding supplements Anabeutrol and Andritest.
“GNC’s commitment to consumers, reputation for quality, and massive retail muscle is the perfect match for EP2 products,” stated Ryan Keller, director of sales and marketing at EP2. “Because our mission is to develop clinically proven supplements that are safe and extremely effective, partnering with the most successful sports supplement retailer in the world is a natural fit for EP2.”
FDA approves new packaging of Children’s Zyrtec Allergy
ROCKVILLE, Md. The Food and Drug Administration on Friday approved new packaging for McNeil Consumer Healthcare’s Children’s Zyrtec Allergy syrup, grape sugar-free, dye-free flavor, in a letter addressed to the supplier.
The new packaging will include a prefilled dosing spoon that will deliver a single dose, or 5 mg, of Zyrtec (cetirizine).
LifeScan, Apple demonstrate prototype diabetes management software
MILPITAS, Calif. Johnson & Johnson’s LifeScan on Tuesday demonstrated a prototype diabetes management software application, integrating the company’s OneTouch blood glucose meters with the Apple iPhone and iPod touch products. LifeScan was one of a handful of companies invited by Apple to develop and preview innovative new applications at Apple’s iPhone OS 3.0 software event, the company stated.
Using a modified OneTouch Meter, the prototype application demonstrated transmission of a blood glucose test result to the Apple iPhone. Once on the iPhone, test results were available for integration with other information in a series of user-friendly graphics, including the user’s level of glucose control over time relative to targets established with his or her healthcare professional.
The application also will include a customizable food database to help users determine the amount of carbohydrates consumed during meals. Future applications also may include the capability for users to calculate a bolus insulin dose based on the last glucose result and the number of carbohydrates that will be consumed.
The new OneTouch/iPhone application is in the early stages of development, the company noted.